Exploratory Study of Relationships Between Malodor and Urine Metabolomics
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02683876 |
Recruitment Status :
Completed
First Posted : February 17, 2016
Results First Posted : October 23, 2020
Last Update Posted : October 23, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Nutritional and Metabolic Diseases |
Study Type : | Observational |
Actual Enrollment : | 39 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Metabolomic Profiling of Urine Samples for the Identification of Novel Biomarkers and Mechanisms in the Diagnosis and Management of Malodor Associated With Metabolic Inefficiencies |
Actual Study Start Date : | February 2016 |
Actual Primary Completion Date : | August 30, 2017 |
Actual Study Completion Date : | May 2018 |

Group/Cohort |
---|
Subjects with malodor
individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
|
Healthy control
individuals not complaining of uncontrollable or unpredictable malodor episodes
|
- Differences in Metabolite Concentrations in Urine Between Individuals With Malodor Issues and Age-matched Healthy Controls. [ Time Frame: time from diagnostic urine sample collection to dispatch of results ]
The investigators would like to validate if urine metabolomic profiling can be used for identifying key metabolomic signatures associated with malodor.
Differences in metabolite concentrations will be measured by mass spectrometry, to compare urine samples from individuals with malodor issues, and age-matched healthy controls.
- Correlations Between Urine Biomarkers and Frequency/Severity of Malodor Symptoms (Questionnaires) [ Time Frame: time from sample collection to notification of results and follow-up needed. ]The investigators will comprehensively analyze the ability of metabolite levels to discriminate frequent and severe from less severe malodor symptoms. The severity of the disease was assessed trough interviews (frequency of key symptoms) and prior laboratory tests.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- 18 years or older
- unpredictable and uncontrollable episodes of malodor
- willing and able to ship a urine sample (in the kit provided) by an overnight courier to Edmonton, Alberta, Canada
- good general health
Exclusion Criteria:
- serious medical conditions that require treatment
- conditions that, in the opinion of the investigator, would prevent participation
- under the age of 18
- elect not to participate in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02683876
United States, Florida | |
MeBO Research | |
Miami, Florida, United States, 33175 | |
Canada, Alberta | |
The Metabolomics Innovation Centre | |
Edmonton, Alberta, Canada, T6G 2E9 |
Principal Investigator: | David Wishart, PhD | The Metabolomics Innovation Centre (TMIC) | |
Principal Investigator: | Irene Gabashvili, PhD | MeBo Research |
Documents provided by Mebo Research, Inc.:
Publications of Results:
Other Publications:
Responsible Party: | Mebo Research, Inc. |
ClinicalTrials.gov Identifier: | NCT02683876 |
Other Study ID Numbers: |
201505010014MEBO |
First Posted: | February 17, 2016 Key Record Dates |
Results First Posted: | October 23, 2020 |
Last Update Posted: | October 23, 2020 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | to prevent risks of re-identification. |
body odor, malodor, halitosis |
Metabolic Diseases |